Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2026)

Adaptive Biotechnologies has reported Cash & Equivalents for 9 years, with the latest figure at $77.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 53.18% year-over-year to $77.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.6 million (up 53.18% YoY) and the FY2025 annual result came in at $70.5 million, up 47.11% from the prior year.
• Cash & Equivalents advanced to $77.6 million in Q1 2026 per ADPT's latest filing, from $70.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $217.6 million in Q3 2022 and troughed at $38.1 million in Q3 2024.
• A 5-year average of $80.6 million and a median of $71.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 77.74% in 2022, then slumped 59.22% in 2023.
• Over 5 years, Cash & Equivalents stood at $90.0 million in 2022, then dropped by 27.73% to $65.1 million in 2023, then declined by 26.35% to $47.9 million in 2024, then soared by 47.11% to $70.5 million in 2025, then gained by 10.05% to $77.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $77.6 million, $70.5 million, and $55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.